Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 13.20% is 14% above its 5-year average of 11.53%, around the middle of its 5-year range (-8.65%–26.93%).
2.37% below its 12-month average of 13.52%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 5.49%.
RETURN ON ASSETS (ROA)
13.20%
RETURN ON ASSETS (ROA) AVG TTM
13.52%
RETURN ON ASSETS (ROA) AVG 3Y
17.46%
RETURN ON ASSETS (ROA) AVG 5Y
11.53%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.37%
CURRENT VS 3Y AVG
-24.41%
CURRENT VS 5Y AVG
+14.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.77%
median of 814 covered companies
CURRENT VS SECTOR MEDIAN
+141.55%
vs the sector median at left
Harmony Biosciences Holdings, Inc.
Market Cap
$2.27B
Return on Assets (ROA)
13.20%
TTM Avg
13.52%
3Y Avg
17.46%
5Y Avg
11.53%
Market Cap
$2.28B
Return on Assets (ROA)
-12.82%
TTM Avg
-15.67%
3Y Avg
-7.42%
5Y Avg
-2.36%
Market Cap
$2.31B
Return on Assets (ROA)
-63.74%
TTM Avg
-33.67%
3Y Avg
-37.78%
5Y Avg
-31.10%
Market Cap
$2.33B
Return on Assets (ROA)
26.56%
TTM Avg
-38.82%
3Y Avg
-43.93%
5Y Avg
-45.44%
Market Cap
$2.35B
Return on Assets (ROA)
24.69%
TTM Avg
32.00%
3Y Avg
9.13%
5Y Avg
-4.32%
Market Cap
$2.38B
Return on Assets (ROA)
-42.79%
TTM Avg
-37.88%
3Y Avg
-40.02%
5Y Avg
-36.63%
Market Cap
$2.40B
Return on Assets (ROA)
-21.30%
TTM Avg
-10.65%
3Y Avg
-10.65%
5Y Avg
-10.65%
Market Cap
$2.40B
Return on Assets (ROA)
-2.55%
TTM Avg
-11.61%
3Y Avg
-25.65%
5Y Avg
-35.91%
Market Cap
$2.15B
Return on Assets (ROA)
-53.05%
TTM Avg
-52.17%
3Y Avg
-43.79%
5Y Avg
-37.43%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | $2.27B | 13.20% | 13.52% | 17.46% | 11.53% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | -12.82% | -15.67% | -7.42% | -2.36% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.31B | -63.74% | -33.67% | -37.78% | -31.10% |
| Liquidia Corporation (LQDA)vs › | $2.33B | 26.56% | -38.82% | -43.93% | -45.44% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.35B | 24.69% | 32.00% | 9.13% | -4.32% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.38B | -42.79% | -37.88% | -40.02% | -36.63% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.40B | -21.30% | -10.65% | -10.65% | -10.65% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -2.55% | -11.61% | -25.65% | -35.91% |
| Pharvaris N.V. (PHVS)vs › | $2.15B | -53.05% | -52.17% | -43.79% | -37.43% |
| Disc Medicine, Inc. (IRON)vs › | $2.41B | -33.45% | -24.16% | -23.12% | -103.71% |
ROA
13.2%
ROE
18.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 12.48% |
| 2024-12-31 | 14.56% |
| 2023-12-31 | 15.88% |
| 2022-12-31 | 26.93% |
| 2021-12-31 | 7.98% |
| 2020-12-31 | -8.65% |
| 2019-12-31 | -142.43% |
| 2018-12-31 | -44.69% |
